▲ Peaking
Business
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Juvmo
2 trends tracked about this subject — the full history, oldest to newest below.
↓ Cooling
Business
New Parkinson’s drug approved in the US: What does it do differently?
The U.S. FDA has approved AbbVie's Juvmo, a first-in-class medication designed to provide a next-generation treatment option for Parkinson's disease.